New immune cell therapy targets Hard-to-Treat cancers

NCT ID NCT06218914

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

engineered T cells (NT-112 and AZD0240) targeting KRAS G12D mutation

What this could lead to

If successful, this could lead to a new treatment option for people with advanced cancers that have a specific KRAS mutation, potentially shrinking tumors or slowing disease progression.

What could go wrong

This is a very early (Phase 1) trial with only 108 participants, so safety and effectiveness are not yet proven. The treatment may cause serious side effects, and it only works for people with a specific genetic profile (KRAS G12D and certain HLA types).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal carcinoma colorectal neoplasm endometrial cancer endometrium neoplasm neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA ENDOMETRIAL CANCER KRAS G12D NON-SMALL-CELL LUNG CANCER PANCREATIC DUCTAL ADENOCARCINOMA SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Duarte, California, 91010, United States
Research Site
RECRUITING

Los Angeles, California, 90095, United States
Research Site
RECRUITING

Newport Beach, California, 92663, United States
Research Site
RECRUITING

Jacksonville, Florida, 32224, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
RECRUITING

Westwood, Kansas, 66205, United States
Research Site
RECRUITING

Boston, Massachusetts, 02115, United States
Research Site
RECRUITING

St Louis, Missouri, 63110, United States
Research Site
RECRUITING

New York, New York, 10016, United States
Research Site
RECRUITING

New York, New York, 10065, United States
Research Site
RECRUITING

Portland, Oregon, 97213, United States
Research Site
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Research Site
RECRUITING

Pittsburgh, Pennsylvania, 15237, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
RECRUITING

Dallas, Texas, 75246, United States
Research Site
RECRUITING

Galveston, Texas, 77555, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Milwaukee, Wisconsin, 53226, United States